Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

21 - 30of about 630 News

21 - 30of about 630 News

March 12, 2021

Elections at the Annual Stockholders' Meeting on April 27, 2021:

Bayer to further strengthen expertise and international profile of its Supervisory Board

March 10, 2021

Capital Markets Day 2021:

Bayer expects dynamic growth with higher profitability in the coming years and is accelerating its transformation

February 25, 2021

Fiscal 2020:

Bayer delivers robust performance despite pandemic – foundation laid for future growth

February 24, 2021

Bayer to Divest Environmental Science Professional Business and Further Strengthen Leadership Team of Crop Science Division

February 09, 2021

Not intended for U.S. and UK Media

Bayer submits finerenone for marketing authorization in China for the treatment of chronic kidney disease in type 2 diabetes

February 08, 2021

Not intended for U.S. and UK Media

New data presented at 2021 ASCO GU Cancers Symposium add to robustness of the overall survival benefit and favorable safety profile for Nubeqa™

February 08, 2021

Not intended for U.S. and UK Media

Bayer and Orion expand development program for darolutamide in prostate cancer

February 03, 2021

Bayer announces agreement with plaintiffs’ counsel on class plan

February 03, 2021

Not intended for U.S. and UK Media

Bayer receives approval for Nubeqa™ in China for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC)

January 20, 2021

Not intended for U.S. and UK Media

U.S. FDA approves vericiguat for patients with symptomatic chronic heart failure

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases